Cholesterol emboli syndrome risk factors: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Cholesterol emboli syndrome}} | {{Cholesterol emboli syndrome}} | ||
{{CMG}} | {{CMG}} {{AE}}{{NN}} | ||
==Overview== | ==Overview== | ||
The most potent risk factor in the development of [[cholesterol emboli syndrome]] is [[atherosclerosis]]. Other risk factors include [[cardiovascular]] interventions such as [[angiography]] and [[cardiovascular]] surgery, [[aortic aneurysm]], [[diabetes mellitus]], [[hypertension]], [[dyslipidemia]], [[smoking]], [[aging]], [[male]] sex, [[anticoagulants]] such as [[warfarin]], [[thrombolytic]] therapy and higher serum [[CRP]] levels. | |||
==Risk Factors== | ==Risk Factors== | ||
* | |||
*The most potent risk factor in the development of [[cholesterol emboli syndrome]] is [[atherosclerosis]]. <ref name="Ozkok2019">{{cite journal|last1=Ozkok|first1=Abdullah|title=<p>Cholesterol-embolization syndrome: current perspectives</p>|journal=Vascular Health and Risk Management|volume=Volume 15|year=2019|pages=209–220|issn=1178-2048|doi=10.2147/VHRM.S175150}}</ref> | |||
* | *Other risk factors include<ref name="Ozkok2019">{{cite journal|last1=Ozkok|first1=Abdullah|title=<p>Cholesterol-embolization syndrome: current perspectives</p>|journal=Vascular Health and Risk Management|volume=Volume 15|year=2019|pages=209–220|issn=1178-2048|doi=10.2147/VHRM.S175150}}</ref><ref name="SaklayenGupta2016">{{cite journal|last1=Saklayen|first1=Mohammad G.|last2=Gupta|first2=Satyendra|last3=Suryaprasad|first3=Agaram|last4=Azmeh|first4=Wayel|last5=Saklayen|first5=Mohammad G.|title=Incidence of Atheroembolic Renal Failure After Coronary Angiography|journal=Angiology|volume=48|issue=7|year=2016|pages=609–613|issn=0003-3197|doi=10.1177/000331979704800707}}</ref><ref name="FukumotoTsutsui2003">{{cite journal|last1=Fukumoto|first1=Yoshihiro|last2=Tsutsui|first2=Hiroyuki|last3=Tsuchihashi|first3=Miyuki|last4=Masumoto|first4=Akihiro|last5=Takeshita|first5=Akira|title=The incidence and risk factors of cholesterol embolization syndrome, a complication of cardiac catheterization: a prospective study|journal=Journal of the American College of Cardiology|volume=42|issue=2|year=2003|pages=211–216|issn=07351097|doi=10.1016/S0735-1097(03)00579-5}}</ref><ref name="HymanLandas1987">{{cite journal|last1=Hyman|first1=Bradley T.|last2=Landas|first2=Steve K.|last3=Ashman|first3=Robert F.|last4=Schelper|first4=Robert L.|last5=Robinson|first5=Robert A.|title=Warfarin-related purple toes syndrome and cholesterol microembolization|journal=The American Journal of Medicine|volume=82|issue=6|year=1987|pages=1233–1237|issn=00029343|doi=10.1016/0002-9343(87)90231-2}}</ref><ref name="VarisKuusniemi2010">{{cite journal|last1=Varis|first1=J.|last2=Kuusniemi|first2=K.|last3=Jarvelainen|first3=H.|title=Cholesterol microembolization syndrome: a complication of anticoagulant therapy|journal=Canadian Medical Association Journal|volume=182|issue=9|year=2010|pages=931–933|issn=0820-3946|doi=10.1503/cmaj.090919}}</ref><ref name="HittiWali2008">{{cite journal|last1=Hitti|first1=Wassim A|last2=Wali|first2=Ravinder K|last3=Weiman|first3=Edward J|last4=Drachenberg|first4=Cinthia|last5=Briglia|first5=Andrew|title=Cholesterol Embolization Syndrome Induced by Thrombolytic Therapy|journal=American Journal of Cardiovascular Drugs|volume=8|issue=1|year=2008|pages=27–34|issn=1175-3277|doi=10.2165/00129784-200808010-00004}}</ref>: | ||
* [[ | **[[cardiovascular]] interventions such as [[angiography]], [[cardiovascular]] surgery | ||
* [[ | **[[aortic aneurysm]] | ||
* [[ | **[[diabetes mellitus]] | ||
* | **[[hypertension]] | ||
* | **[[dyslipidemia]] | ||
* | **[[smoking]] | ||
* | **[[aging]] | ||
* | **[[male]] sex | ||
* | **[[anticoagulants]] such as [[warfarin]] | ||
* | **[[thrombolytic]] therapy | ||
**higher serum [[CRP]] levels | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
| Line 23: | Line 29: | ||
[[Category:Vascular surgery]] | [[Category:Vascular surgery]] | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:need English review]] | |||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Latest revision as of 20:40, 3 February 2021
|
Cholesterol emboli syndrome Microchapters |
|
Differentiating Cholesterol emboli syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Cholesterol emboli syndrome risk factors On the Web |
|
American Roentgen Ray Society Images of Cholesterol emboli syndrome risk factors |
|
Directions to Hospitals Treating Cholesterol emboli syndrome |
|
Risk calculators and risk factors for Cholesterol emboli syndrome risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Nasrin Nikravangolsefid, MD-MPH [2]
Overview
The most potent risk factor in the development of cholesterol emboli syndrome is atherosclerosis. Other risk factors include cardiovascular interventions such as angiography and cardiovascular surgery, aortic aneurysm, diabetes mellitus, hypertension, dyslipidemia, smoking, aging, male sex, anticoagulants such as warfarin, thrombolytic therapy and higher serum CRP levels.
Risk Factors
- The most potent risk factor in the development of cholesterol emboli syndrome is atherosclerosis. [1]
- Other risk factors include[1][2][3][4][5][6]:
- cardiovascular interventions such as angiography, cardiovascular surgery
- aortic aneurysm
- diabetes mellitus
- hypertension
- dyslipidemia
- smoking
- aging
- male sex
- anticoagulants such as warfarin
- thrombolytic therapy
- higher serum CRP levels
References
- ↑ 1.0 1.1 Ozkok, Abdullah (2019). "
Cholesterol-embolization syndrome: current perspectives
". Vascular Health and Risk Management. Volume 15: 209–220. doi:10.2147/VHRM.S175150. ISSN 1178-2048. - ↑ Saklayen, Mohammad G.; Gupta, Satyendra; Suryaprasad, Agaram; Azmeh, Wayel; Saklayen, Mohammad G. (2016). "Incidence of Atheroembolic Renal Failure After Coronary Angiography". Angiology. 48 (7): 609–613. doi:10.1177/000331979704800707. ISSN 0003-3197.
- ↑ Fukumoto, Yoshihiro; Tsutsui, Hiroyuki; Tsuchihashi, Miyuki; Masumoto, Akihiro; Takeshita, Akira (2003). "The incidence and risk factors of cholesterol embolization syndrome, a complication of cardiac catheterization: a prospective study". Journal of the American College of Cardiology. 42 (2): 211–216. doi:10.1016/S0735-1097(03)00579-5. ISSN 0735-1097.
- ↑ Hyman, Bradley T.; Landas, Steve K.; Ashman, Robert F.; Schelper, Robert L.; Robinson, Robert A. (1987). "Warfarin-related purple toes syndrome and cholesterol microembolization". The American Journal of Medicine. 82 (6): 1233–1237. doi:10.1016/0002-9343(87)90231-2. ISSN 0002-9343.
- ↑ Varis, J.; Kuusniemi, K.; Jarvelainen, H. (2010). "Cholesterol microembolization syndrome: a complication of anticoagulant therapy". Canadian Medical Association Journal. 182 (9): 931–933. doi:10.1503/cmaj.090919. ISSN 0820-3946.
- ↑ Hitti, Wassim A; Wali, Ravinder K; Weiman, Edward J; Drachenberg, Cinthia; Briglia, Andrew (2008). "Cholesterol Embolization Syndrome Induced by Thrombolytic Therapy". American Journal of Cardiovascular Drugs. 8 (1): 27–34. doi:10.2165/00129784-200808010-00004. ISSN 1175-3277.